Zhifei Biology (300122.SZ): Application for production registration for freeze-dried human rabies vaccine (human diploid cells) was accepted

Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently received a report from its wholly-owned subsidiary, Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (hereinafter referred to as “Zhifeilong Koma”), that the freeze-dried human rabies vaccine (human diploid cells) independently developed by Zhifei Long Koma has applied for production registration and obtained a “Notice of Acceptance” (acceptance number: CXSS2400112) issued by the State Drug Administration.

The freeze-dried human rabies vaccine (human diploid cells), which has been approved for production registration, uses human diploid cells as a culture substrate, and can prevent rabies after vaccination. As of the announcement date, after checking the website of the State Drug Administration, there are 2 freeze-dried human rabies vaccines (human diploid cells) approved for marketing in China. If the project progresses smoothly, it will further enrich the company's virus vaccine varieties, improve the company's product layout, and strengthen the company's competitive advantage in the market.